13.68  0.45 (3.4%)		05-12 16:00
Open: 13.49 High: 14.01 Volume: 73,148		Pre. Close: 13.23 Low: 12.995 Market Cap: 90(M)

Short term
Mid term
Targets	6-month :	22.43	1-year :	28.49
Resists	First :	19.2	Second :	24.39
Pivot price	14.17
Supports	First :	10.8	Second :	8.98
MAs	MA(5) :	13	MA(20) :	14.62
	MA(100) :	19.03	MA(250) :	21.95
MACD	MACD :	-1.1	Signal :	-1.2
%K %D	K(14,3) :	18.4	D(3) :	15.8
RSI	RSI(14): 45.9
52-week	High :	92	Low :	9.61

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TIL ] has closed above bottom band by 45.2%. Bollinger Bands are 34.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	14.03 - 14.09	14.09 - 14.15
Low:	12.86 - 12.92	12.92 - 12.98
Close:	13.59 - 13.69	13.69 - 13.79

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Tue, 04 Mar 2025
Instil Bio Reports 2024 Financial Results and Outlook - TipRanks

Tue, 04 Mar 2025
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Thu, 20 Feb 2025
Private equity firms who hold 38% of Instil Bio, Inc. (NASDAQ:TIL) gained 34%, institutions profited as well - Yahoo Finance

Tue, 14 Jan 2025
Instil Bio Announces Clinical Progress in China for - GlobeNewswire

Sun, 01 Dec 2024
Instil Bio’s Strategic Shift To SYN-2510: A Speculative ‘Buy’ Opportunity (NASDAQ:TIL) - Seeking Alpha

Mon, 16 Sep 2024
Instil Bio Stock Skyrockets 641% in One Week: Here's Why - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	7 (M)
Shares Float	2 (M)
Held by Insiders	6.5 (%)
Held by Institutions	80.3 (%)
Shares Short	562 (K)
Shares Short P.Month	565 (K)

EPS	-11.4
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	25.95
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-12.8 %
Return on Equity (ttm)	-37.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-8.59
Qtrly Earnings Growth	0 %
Operating Cash Flow	-56 (M)
Levered Free Cash Flow	-27 (M)

PE Ratio	-1.21
PEG Ratio	0
Price to Book value	0.52
Price to Sales	0
Price to Cash Flow	-1.62

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.